申请人:Japan Tobacco Inc.
公开号:EP4026564A1
公开(公告)日:2022-07-13
One purpose of the present invention is to provide therapy or prophylaxis of diabetes, obesity, or diabetic complications. The present invention provides a therapeutic or prophylactic medicine that is for diabetes, obesity, or diabetic complications, and that is characterized by combinational use of an SGLT1 inhibitor and at least one drug selected from SGLT2 inhibitors and DPP4 inhibitors; and a therapeutic or prophylactic method that is for diabetes, obesity, or diabetic complications, and that is characterized by administering an SGLT1 inhibitor and at least one drug selected from SGLT2 inhibitors and DPP4 inhibitors.
本发明的一个目的是提供糖尿病、肥胖症或糖尿病并发症的治疗或预防。本发明提供了一种治疗或预防糖尿病、肥胖症或糖尿病并发症的药物,其特点是联合使用SGLT1抑制剂和至少一种从SGLT2抑制剂和DPP4抑制剂中选择的药物;以及一种治疗或预防糖尿病、肥胖症或糖尿病并发症的治疗方法,其特点是给予SGLT1抑制剂和至少一种从SGLT2抑制剂和DPP4抑制剂中选择的药物。